231 related articles for article (PubMed ID: 11473532)
1. Effects of dopamine d2 receptor agonists in a pituitary transplantation-induced hyperprolactinaemia/anovulation model in rats.
Moro M; Inada Y; Miyata H; Komatsu H; Kojima M; Tsujii H
Clin Exp Pharmacol Physiol; 2001 Aug; 28(8):651-8. PubMed ID: 11473532
[TBL] [Abstract][Full Text] [Related]
2. New hyperprolactinemia and anovulation model in common marmoset (Callithrix jacchus) and effect of cabergoline.
Moro M; Inada Y; Kojima M; Miyata H; Komatsu H; Torii R
Eur J Pharmacol; 1999 Feb; 368(1):57-66. PubMed ID: 10096770
[TBL] [Abstract][Full Text] [Related]
3. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.
Rains CP; Bryson HM; Fitton A
Drugs; 1995 Feb; 49(2):255-79. PubMed ID: 7729332
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic activity of sarpogrelate and dopamine D
Fouad Shalaby MA; Abd El Latif HA; El Yamani M; Galal MA; Kamal S; Sindi I; Masaood R
BMC Pharmacol Toxicol; 2021 Oct; 22(1):64. PubMed ID: 34702339
[TBL] [Abstract][Full Text] [Related]
6. Hyperprolactinaemia and pituitary adenomas in adolescence.
Dissaneevate P; Warne GL
J Pediatr Endocrinol Metab; 1998; 11(4):531-41. PubMed ID: 9777574
[TBL] [Abstract][Full Text] [Related]
7. Terguride as a new anti-hyperprolactinemic agent: characterization in rats and dogs in comparison with bromocriptine.
Mizokawa T; Akai T; Nakada Y; Yamaguchi M; Nakagawa H; Hasan S; Rettig KJ; Wachtel H
Jpn J Pharmacol; 1993 Nov; 63(3):269-78. PubMed ID: 7906316
[TBL] [Abstract][Full Text] [Related]
8. Cabergoline: a new drug for the treatment of hyperprolactinaemia.
Ferrari C; Piscitelli G; Crosignani PG
Hum Reprod; 1995 Jul; 10(7):1647-52. PubMed ID: 8582955
[TBL] [Abstract][Full Text] [Related]
9. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation.
Webster J
Drug Saf; 1996 Apr; 14(4):228-38. PubMed ID: 8713691
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
Sabuncu T; Arikan E; Tasan E; Hatemi H
Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
[TBL] [Abstract][Full Text] [Related]
11. Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels.
Krysiak R; Okopien B
Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):251-6. PubMed ID: 25123447
[TBL] [Abstract][Full Text] [Related]
12. Hyperprolactinaemia and female infertility.
Godó G
Acta Med Hung; 1984; 41(4):185-93. PubMed ID: 6440115
[TBL] [Abstract][Full Text] [Related]
13. Current treatment issues in female hyperprolactinaemia.
Crosignani PG
Eur J Obstet Gynecol Reprod Biol; 2006 Apr; 125(2):152-64. PubMed ID: 16288952
[TBL] [Abstract][Full Text] [Related]
14. Paeoniflorin ameliorates antipsychotic-induced hyperprolactinemia in rats by attenuating impairment of the dopamine D2 receptor and TGF-β1 signaling pathways in the hypothalamus and pituitary.
Huang X; Ren L; Hou L; Fan H; Wang C; Wang C; Li Y
J Ethnopharmacol; 2020 Jul; 257():112862. PubMed ID: 32294507
[TBL] [Abstract][Full Text] [Related]
15. Incidence and significance of hyperprolactinaemia in women with amenorrhea.
Franks S; Murray MA; Jequier AM; Steele SJ; Nabarro JD; Jacobs HS
Clin Endocrinol (Oxf); 1975 Nov; 4(6):597-607. PubMed ID: 1104218
[TBL] [Abstract][Full Text] [Related]
16. Effect of mesulergine on prolactin secretion and dopamine D2 receptors-adaptive changes in diethylstilbestrol-induced hyperplasia of the rat anterior pituitary.
Pisarek H; Stepien H; Pawlikowski M
Endocr Regul; 1992 Mar; 26(1):17-22. PubMed ID: 1421203
[TBL] [Abstract][Full Text] [Related]
17. Dopamine receptor affinities in vitro and stereotypic activities in vivo of cabergoline in rats.
Miyagi M; Itoh F; Taya F; Arai N; Isaji M; Kojima M; Ujiie A
Biol Pharm Bull; 1996 Sep; 19(9):1210-3. PubMed ID: 8889042
[TBL] [Abstract][Full Text] [Related]
18. Sleep and local field potential effect of the D2 receptor agonist bromocriptine during the estrus cycle and postpartum period in female rats.
Tóth A; Keserű D; Pethő M; Détári L; Bencsik N; Dobolyi Á; Hajnik T
Pharmacol Biochem Behav; 2024 Jun; 239():173754. PubMed ID: 38537873
[TBL] [Abstract][Full Text] [Related]
19. [Hyperprolactinemic amenorrhea:treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study].
Pascal-Vigneron V; Weryha G; Bosc M; Leclere J
Presse Med; 1995 Apr; 24(16):753-7. PubMed ID: 7784413
[TBL] [Abstract][Full Text] [Related]
20. Effects of bromocriptine on serum prolactin levels, pituitary weight and immunoreactive prolactin cells in estradiol-treated ovariectomized rats: an experimental model of estrogen-dependent hyperprolactinemia.
Ribeiro MF; Spritzer PM; Barbosa-Coutinho LM; Oliveira MC; Pavanato MA; Silva IS; Reis FM
Braz J Med Biol Res; 1997 Jan; 30(1):113-7. PubMed ID: 9222412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
